PMID- 23216087
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20220330
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 27
IP  - 6
DP  - 2013 Dec
TI  - Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on 
      motor and cognitive functions in a rat model of Parkinson's disease.
PG  - 632-40
LID - 10.1111/fcp.12015 [doi]
AB  - TRPV1 receptors and cannabinoid system are considered as important modulators of 
      basal ganglia functions, and their pharmacologic manipulation represents a 
      promising therapy to alleviate Parkinson-induced hypokinesia. Recent evidence 
      suggests that the blockade of cannabinoid receptors might be beneficial to 
      alleviate motor deficits observed in Parkinson's disease. In the present study, 
      we have evaluated the effects of AMG9810 , a selective antagonist of TRPV1 
      receptors, on the motor and cognitive functions in a rat model of Parkinson's 
      disease generated by an intracerebroventricular injection of 6- hydroxydopamine 
      (6-OHDA) (200 mug per animal). The injection of 10 nmol of AMG9810 for a single 
      dose (AMG1) and for 2 weeks (AMG14) partially attenuated the hypokinesia shown by 
      these animals in motor function evaluation tests, whereas chronic administration 
      of AMG had destructive effects on learning and memory in 6-OHDA-treated rats. 
      Animals in the AMG 1 and AMG 14 groups showed an increased latency to fall in 
      rotarod and grasping tests in each trials compared with 6-OHDA-treated rats (P < 
      0.01) and DMSO 1 and 14 groups (P < 0.05). Our data indicate that pharmacological 
      blockade of TRPV1 receptors by AMG 9810 attenuates the hypokinetic effects of 
      6-OHDA and that TRPV1 receptors play an important role in 6-OHDA-induced 
      hypokinesia, although elucidation of the neurochemical substrate involved in this 
      process remains a major challenge for the future.
CI  - (c) 2012 The Authors Fundamental and Clinical Pharmacology (c) 2012 Societe Francaise 
      de Pharmacologie et de Therapeutique.
FAU - Razavinasab, Moazamehosadat
AU  - Razavinasab M
AD  - Physiology - Pharmacology Research Center, Rafsanjan University of Medical 
      Sciences, Rafsanjan, Iran.
FAU - Shamsizadeh, Ali
AU  - Shamsizadeh A
FAU - Shabani, Mohammad
AU  - Shabani M
FAU - Nazeri, Masoud
AU  - Nazeri M
FAU - Allahtavakoli, Mohammad
AU  - Allahtavakoli M
FAU - Asadi-Shekaari, Majid
AU  - Asadi-Shekaari M
FAU - Esmaeli-Mahani, Saeed
AU  - Esmaeli-Mahani S
FAU - Sheibani, Vahid
AU  - Sheibani V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121205
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide)
RN  - 0 (Acrylamides)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (TRPV Cation Channels)
RN  - 0 (TRPV1 receptor)
RN  - 8HW4YBZ748 (Oxidopamine)
SB  - IM
MH  - Acrylamides/administration & dosage/*pharmacology
MH  - Animals
MH  - Bridged Bicyclo Compounds, Heterocyclic/administration & dosage/*pharmacology
MH  - Cognition/drug effects
MH  - Disease Models, Animal
MH  - Male
MH  - Motor Activity/drug effects
MH  - Neuroprotective Agents/administration & dosage/pharmacology
MH  - Oxidopamine/*toxicity
MH  - Parkinsonian Disorders/*drug therapy/physiopathology
MH  - Rats
MH  - Rats, Wistar
MH  - TRPV Cation Channels/*antagonists & inhibitors
OTO - NOTNLM
OT  - 6- Hydroxydopamine
OT  - AMG
OT  - cognitive function
OT  - motor function
EDAT- 2012/12/12 06:00
MHDA- 2014/06/03 06:00
CRDT- 2012/12/11 06:00
PHST- 2012/08/08 00:00 [received]
PHST- 2012/10/25 00:00 [revised]
PHST- 2012/10/31 00:00 [accepted]
PHST- 2012/12/11 06:00 [entrez]
PHST- 2012/12/12 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
AID - 10.1111/fcp.12015 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2013 Dec;27(6):632-40. doi: 10.1111/fcp.12015. Epub 2012 
      Dec 5.